• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依替巴肽致一名盆腔恶性肿瘤患者严重血小板减少症：病例报告

Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report.

作者信息

Squires Kathryn C, Guntupalli Saketh R, Thaker Premal H

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, Saint Louis, MO, USA.

出版信息

Gynecol Oncol Case Rep. 2012 Mar 14;2(3):75-7. doi: 10.1016/j.gynor.2012.03.002. eCollection 2012.

DOI:10.1016/j.gynor.2012.03.002
PMID:24371624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3860694/
Abstract

► Eptifibatide is associated with profound thrombocytopenia and thrombosis secondary to a HITT-like mechanism associated with drug-dependant antibodies. ► Caution with eptifibatide use is needed in those pre-disposed to hypercoaguability, particularly those with an underlying malignancy.

摘要

► 依替巴肽与严重血小板减少症和血栓形成有关，其继发于与药物依赖性抗体相关的类肝素诱导的血小板减少症（HITT）样机制。► 对于那些易发生高凝状态的患者，尤其是那些患有潜在恶性肿瘤的患者，使用依替巴肽时需要谨慎。

相似文献

1
Eptifibatide induced profound thrombocytopenia in a patient with pelvic malignancy: A case report.依替巴肽致一名盆腔恶性肿瘤患者严重血小板减少症：病例报告
Gynecol Oncol Case Rep. 2012 Mar 14;2(3):75-7. doi: 10.1016/j.gynor.2012.03.002. eCollection 2012.
2
Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.依替巴肽诱导的人类血小板减少症和血栓形成需要FcγRIIa和整合素β3胞质结构域。
J Clin Invest. 2009 Mar;119(3):504-11. doi: 10.1172/JCI36745. Epub 2009 Feb 9.
3
In vivo platelet redistribution and acute transient thrombocytopenia after eptifibatide injection in baboons.巴弗洛霉素 A1 注射后狒狒体内血小板的重新分布及急性短暂性血小板减少症
Thromb Res. 2005;115(1-2):79-87. doi: 10.1016/j.thromres.2004.06.044.
4
Profound thrombocytopenia after primary exposure to eptifibatide.初次接触依替巴肽后出现严重血小板减少症。
Drug Healthc Patient Saf. 2010;2:163-7. doi: 10.2147/DHPS.S13239. Epub 2010 Sep 21.
5
Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Am J Cardiol. 1997 Aug 18;80(4A):29B-33B. doi: 10.1016/s0002-9149(97)00574-2.
6
Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.依替巴肽诱导的血小板减少症：在左主干冠状动脉经皮冠状动脉介入治疗后立即出现血栓形成和弥散性血管内凝血。
Tex Heart Inst J. 2012;39(1):86-91.
7
Eptifibatide-induced acute profound thrombocytopenia: a case report.依替巴肽诱发的急性严重血小板减少症：一例报告
BMC Res Notes. 2014 Feb 25;7:107. doi: 10.1186/1756-0500-7-107.
8
Eptifibatide-associated acute, profound thrombocytopenia.依替巴肽相关的急性、严重血小板减少症。
Ann Pharmacother. 2005 Feb;39(2):368-72. doi: 10.1345/aph.1E244. Epub 2005 Jan 11.
9
Eptifibatide-induced thrombocytopenia leading to acute stent thrombosis.依替巴肽诱导的血小板减少症导致急性支架血栓形成。
J Thromb Thrombolysis. 2016 Apr;41(3):522-4. doi: 10.1007/s11239-015-1270-y.
10
Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.依替巴肽再次给药相关的急性严重血小板减少症：病例报告及文献综述
Pharmacotherapy. 2009 Jul;29(7):867-74. doi: 10.1592/phco.29.7.867.

引用本文的文献

1
Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction.依替巴肽与肝硬化：重新审视用于肝功能不全背景下急性冠脉综合征的糖蛋白IIb-IIIa抑制剂
Cardiol Res. 2014 Dec;5(6):191-194. doi: 10.14740/cr357w. Epub 2014 Dec 4.

本文引用的文献

1
Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial.非 ST 段抬高型急性冠脉综合征患者支架血栓形成的预测因素及意义：ACUITY 试验。
Circ Cardiovasc Interv. 2011 Dec 1;4(6):577-84. doi: 10.1161/CIRCINTERVENTIONS.111.963884. Epub 2011 Oct 25.
2
The roles of platelet GPIIb/IIIa and alphavbeta3 integrins during HeLa cells adhesion, migration, and invasion to monolayer endothelium under static and dynamic shear flow.血小板糖蛋白IIb/IIIa和αvβ3整合素在静态和动态剪切流条件下HeLa细胞黏附、迁移及侵袭单层内皮细胞过程中的作用
J Biomed Biotechnol. 2009;2009:829243. doi: 10.1155/2009/829243. Epub 2009 Oct 28.
3
Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.依替巴肽再次给药相关的急性严重血小板减少症：病例报告及文献综述
Pharmacotherapy. 2009 Jul;29(7):867-74. doi: 10.1592/phco.29.7.867.
4
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.药物洗脱支架与裸金属支架的观察性队列研究中药物洗脱支架置入后支架内血栓形成、临床事件及氯吡格雷长期使用的影响
JACC Cardiovasc Interv. 2008 Oct;1(5):494-503. doi: 10.1016/j.jcin.2008.06.011.
5
Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.依替巴肽诱导的抗体导致巨核细胞损伤，引起血小板减少症持续时间延长。
Blood. 2009 Aug 6;114(6):1250-3. doi: 10.1182/blood-2009-02-203034. Epub 2009 May 8.
6
Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.依替巴肽诱导的人类血小板减少症和血栓形成需要FcγRIIa和整合素β3胞质结构域。
J Clin Invest. 2009 Mar;119(3):504-11. doi: 10.1172/JCI36745. Epub 2009 Feb 9.
7
Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.使用替罗非班或依替巴肽治疗后出现的急性血小板减少症与针对配体占据的糖蛋白IIb/IIIa的特异性抗体有关。
Blood. 2002 Sep 15;100(6):2071-6.
8
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.β3整合素缺陷小鼠是一种用于研究血小板无力症的模型，表现出胎盘缺陷和存活率降低。
J Clin Invest. 1999 Jan;103(2):229-38. doi: 10.1172/JCI5487.
9
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.依替巴肽抑制急性冠脉综合征患者血小板糖蛋白IIb/IIIa的作用
N Engl J Med. 1998 Aug 13;339(7):436-43. doi: 10.1056/NEJM199808133390704.
10
Uterine carcinosarcomas: incidence and trends in management and survival.子宫癌肉瘤：治疗与生存的发病率及趋势
Gynecol Oncol. 1997 Apr;65(1):158-63. doi: 10.1006/gyno.1997.4629.